Drug Profile

VIP 550

Alternative Names: VIP-550

Latest Information Update: 28 Apr 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bayer
Developer Bayer; Vincerx Pharma
Class Antineoplastics; Camptothecins; Drug conjugates; Small molecules
Mechanism of Action DNA topoisomerase I inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

19 Apr 2023 Preclinical trials in Cancer in USA (unspecified route)
17 Apr 2023 Pharmacodynamics and pharmacokinetic data from a preclinical studies in Cancer presented at the Annual Meeting of American Association for Cancer Research (AACR-2023)
08 Oct 2020 Vincera Pharma singed an licensing agreement with Bayer for development and commercialisation of Oncology Portfolio

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com